Lupus Rheumatoid Arthritis Type 1 Diabetes Systemic Lupus Erythematosus Dermatomyositis Psoriasis ANCA-Associated Vasculitis Multiple Sclerosis Vasculitis Rare Diseases Treatment Strategies Research Alopecia Areata Stiff Person Syndrome Rheumatology Sjögren’s Disease Clinical Trials Treatment Options Crohn's Disease Chronic Illness Hashimoto's Disease Family Health Issues Drug Development Therapeutic Approaches Kidney Diseases ANCA-associated Vasculitis Autoimmune Hemolytic Anemia Inflammation Dermatology Drug Treatments Vitiligo Immune Thrombocytopenia B-cell Disorders Myocarditis Autoimmune Gastritis Eye Inflammation Treatment Innovations B Cell-Mediated Autoimmune Diseases Neurologic Syndromes T Cell Reactivity IgA Nephropathy Therapeutics T-regulatory Cells Granulomatosis with Polyangiitis Sjögren's Disease Treatment Gender Bias Psoriatic Arthritis Treatment Methods Stiff-Person Syndrome Thyroid Disorders Disease Confirmation B-cell Malignancies Neurological Disorders Immunoglobulin G4-Related Disease
Want to see what podcasts are saying about this topic? Search across 135K+ podcasts. Explore Radar
Regulators cited phase 3 VALOR data showing sustained muscle and skin benefit, with the drug’s label carrying a boxed warning for serious infections, cardiovascular events, cancer, and thrombosis.
